CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
淋巴瘤 CAR-T 细胞治疗后早期 18F-FDG PET 反跳现象
英文原题：Early 18F-FDG PET Flare-up Phenomenon After CAR T-Cell Therapy in Lymphoma.
查看英文原题
Early 18F-FDG PET Flare-up Phenomenon After CAR T-Cell Therapy in Lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
对一名难治性弥漫大B细胞淋巴瘤患者进行了一系列18F-FDG PET/CT检查，以监测嵌合抗原受体（CAR）T细胞治疗。由于临床状况恶化，CAR-T 细胞治疗后第8天进行的18F-FDG PET/CT提示早期 flare-up（病灶反跳）现象：出现新的淋巴结受累、淋巴结进展，同时代谢性肿瘤体积下降。CAR-T 细胞治疗后1个月的18F-FDG PET/CT证实了这一判断。既往报告的实体瘤免疫治疗假性进展通常发生在治疗后较晚时期。
展开英文摘要原文
18F-FDG PET/CT imaging series were acquired on a 64-year-old woman with refractory diffuse large B lymphoma to monitor chimeric antigen receptor (CAR) T-cell therapy. Because of a clinical deterioration, 18F-FDG PET/CT performed 8 days after CAR T-cell therapy suggested an early flare-up phenomenon with new lymph node involvement, lymph node progression while a decrease in metabolic tumor volume.
The 18F-FDG PET/CT 1 month after CAR T-cell therapy confirmed this hypothesis. Pseudoprogression in solid tumors treated by immunotherapy has generally been reported later after treatment.
论文信息
- 作者
- Boursier C、Perrin M、Bordonne M、Campidelli A、Verger A
- 第一作者单位
- From the Department of Nuclear Medicine and Nancyclotep Imaging Platform.
- 文献类型
- 病例报告
- 期刊
- Clinical nuclear medicine2022 Feb 1
- 原文标识
- PubMed 34406181 · DOI 10.1097/RLU.0000000000003870